JPWO2023033022A1 - - Google Patents

Info

Publication number
JPWO2023033022A1
JPWO2023033022A1 JP2023545630A JP2023545630A JPWO2023033022A1 JP WO2023033022 A1 JPWO2023033022 A1 JP WO2023033022A1 JP 2023545630 A JP2023545630 A JP 2023545630A JP 2023545630 A JP2023545630 A JP 2023545630A JP WO2023033022 A1 JPWO2023033022 A1 JP WO2023033022A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023545630A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2023033022A1 publication Critical patent/JPWO2023033022A1/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023545630A 2021-08-31 2022-08-31 Pending JPWO2023033022A1 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021141625 2021-08-31
PCT/JP2022/032709 WO2023033022A1 (ja) 2021-08-31 2022-08-31 脱グリコシル化抗体の放射性複合体、及び、放射性医薬

Publications (1)

Publication Number Publication Date
JPWO2023033022A1 true JPWO2023033022A1 (cg-RX-API-DMAC7.html) 2023-03-09

Family

ID=85411332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023545630A Pending JPWO2023033022A1 (cg-RX-API-DMAC7.html) 2021-08-31 2022-08-31

Country Status (6)

Country Link
US (1) US20240316228A1 (cg-RX-API-DMAC7.html)
EP (1) EP4397320A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2023033022A1 (cg-RX-API-DMAC7.html)
CN (1) CN118159305A (cg-RX-API-DMAC7.html)
TW (1) TW202325343A (cg-RX-API-DMAC7.html)
WO (1) WO2023033022A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022080481A1 (cg-RX-API-DMAC7.html) * 2020-10-16 2022-04-21
CA3215787A1 (en) * 2021-03-31 2022-10-06 Nihon Medi-Physics Co., Ltd. Radioactive complex of anti-egfr antibody, and radiopharmaceutical
JPWO2022224980A1 (cg-RX-API-DMAC7.html) * 2021-04-20 2022-10-27
AU2024234975A1 (en) * 2023-03-15 2025-09-18 Kagoshima University Method for producing radiolabeled antibody, radiolabeled antibody, and radiopharmaceutical

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4334141B2 (ja) * 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
JP6872181B2 (ja) 2015-05-20 2021-05-19 国立大学法人 鹿児島大学 IgG結合ペプチドによる抗体の特異的修飾
EP3418304B1 (en) 2016-02-15 2021-08-04 Kanagawa Prefectural Hospital Organization Recognition of membrane type mucin-like protein and clinical application thereof
DK3470418T3 (da) 2016-06-13 2024-09-30 Univ Kagoshima Site-specifik radioisotop-mærket antistof ved brug af using iggbindende peptid
WO2018230257A1 (ja) 2017-06-16 2018-12-20 国立大学法人鹿児島大学 IgG結合ペプチド、及び該ペプチドによる抗体の特異的修飾
JP2021506842A (ja) * 2017-12-18 2021-02-22 ヤンセン バイオテツク,インコーポレーテツド ポリペプチドの放射性標識
TW202504917A (zh) 2018-06-21 2025-02-01 美商再生元醫藥公司 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法
ES3075769T3 (en) * 2019-05-10 2026-08-07 Janssen Biotech Inc Macrocyclic chelators and methods of use thereof
PH12022550894A1 (en) * 2019-10-18 2023-03-27 Nihon Mediphysics Co Ltd Ri-labeled humanized antibody
CN114555132A (zh) * 2019-10-18 2022-05-27 日本医事物理股份有限公司 放射性金属标记抗体的制造方法
JP7291797B2 (ja) 2019-10-18 2023-06-15 住友ファーマ株式会社 ヒト化抗体およびその使用方法
JP7680745B2 (ja) 2019-10-24 2025-05-21 国立大学法人 鹿児島大学 1価ccap生成物の製造方法
JP6827224B1 (ja) 2020-02-29 2021-02-10 隆一 嶋田 通信回線を利用した電力系統安定化システム

Also Published As

Publication number Publication date
TW202325343A (zh) 2023-07-01
WO2023033022A1 (ja) 2023-03-09
EP4397320A4 (en) 2026-08-12
CN118159305A (zh) 2024-06-07
US20240316228A1 (en) 2024-09-26
EP4397320A1 (en) 2024-07-10

Similar Documents

Publication Publication Date Title
CN306556866S (zh) 扣件
CN306091249S (zh) 包装盒
CN305695954S (zh) 包装袋
CN305689366S (zh) 吉他支架(二)
CN305633647S (zh) 玩具(潘多拉魔盒2)
CN305679073S (zh) 经济导读机
CN305686559S (zh) 电气火灾报警器
CN305623275S (zh) 加密钥匙(云系x6)
CN305623823S (zh) 包装箱
CN305679033S (zh) 电脑的用于智能评标系统的图形用户界面
CN305636127S (zh) 球泡灯
CN305630064S (zh) 组合套扫
CN305628369S (zh) 换弹型雾化电子烟
CN305564119S (zh) 板凳(北极熊)
CN305607740S (zh) 智能车钥匙(大黄蜂)
CN305605304S (zh) 泳衣
CN305556112S (zh) 吸黑头仪
CN305566477S (zh) 包装袋袋口卷边机(ⅰ)
CN305577864S (zh) 纽扣
CN305533215S (zh) 鞋用一体针织袜套
CN305531438S (zh) 哑铃训练凳
CN305532057S (zh) 镀铜玻璃护栏
CN305560101S (zh) 按钮开关
CN305588185S (zh) 吊灯(0729下发光圆)
CN305532170S (zh) 射灯(麦克风)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250725